�Next multiplication anticoagulant and antiplatelet agents have shown superiority all over the electric current market leadership in clinical studies and are to challenge them before generics.
The Business Intelligence fast La Merie S.L. reported in its most recent update of the Antithrombotics Competitor Pipeline that sales of the two prima antithrombotics enoxaparin and clopidogrel are rather being challenged by improved innovator drugs than by cheaper generics. The strapping market of major branded antithrombotics in 2007 was US$ 14.9 bln and attracts many companies to grow innovative successors.
The leading anticoagulant enoxaparin is already being challenged by securities industry launch of the number one oral direct thrombin inhibitor from Boehringer Ingelheim.
Oral direct Factor Xa inhibitors are the leading class of anticoagulants having shown superior effects over enoxaparin. Bayer's rivaroxaban is under regulatory
